Some OTC drugs available in the US under a monograph could be removed from the market or need reformulating as the Food and Drug Administration reconsiders the efficacy of oral phenylephrine as a nasal decongestant.
The potential for removing phenylephrine from a monograph could be linked both to nonprescription pseudoephedrine drugs being limited to behind-the-counter sales since 2006 and to the FDA’s ongoing overhaul of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?